Skip to main content
Top
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Research

Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: Is there a role for radiation therapy?

Authors: Rusen Cosar, Cem Uzal, Fusun Tokatli, Bengu Denizli, Mert Saynak, Nesrin Turan, Sernaz Uzunoglu, Alaattin Ozen, Atakan Sezer, Kamuran Ibis, Burcu Uregen, Vuslat Yurut-Caloglu, Zafer Kocak

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Abstract

Background

We aimed to evaluate retrospectively the correlation of loco-regional relapse (LRR) rate, distant metastasis (DM) rate, disease free survival (DFS) and overall survival (OS) in a group of breast cancer (BC) patients who are at intermediate risk for LRR (T1-2 tumor and 1-3 positive axillary nodes) treated with or without postmastectomy radiotherapy (PMRT) following modified radical mastectomy (MRM).

Methods

Ninety patients, with T1-T2 tumor, and 1-3 positive nodes who had undergone MRM received adjuvant systemic therapy with (n = 66) or without (n = 24) PMRT. Patient-related characteristics (age, menopausal status, pathological stage/tumor size, tumor location, histology, estrogen/progesterone receptor status, histological grade, nuclear grade, extracapsular extension, lymphatic, vascular and perineural invasion and ratio of involved nodes/dissected nodes) and treatment-related factors (PMRT, chemotherapy and hormonal therapy) were evaluated in terms of LRR and DM rate. The 5-year Kaplan-Meier DFS and OS rates were analysed.

Results

Differences between RT and no-RT groups were statistically significant for all comparisons in favor of RT group except OS: LRR rate (3%vs 17%, p = 0.038), DM rate (12% vs 42%, p = 0.004), 5 year DFS (82.4% vs 52.4%, p = 0.034), 5 year OS (90,2% vs 61,9%, p = 0.087). In multivariate analysis DM and lymphatic invasion were independent poor prognostic factors for OS.

Conclusion

PMRT for T1-2, N1-3 positive BC patients has to be reconsidered according to the prognostic factors and the decision has to be made individually with the consideration of long-term morbidity and with the patient approval.
Appendix
Available only for authorised users
Literature
1.
go back to reference Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005,365(9472):1687-717. 10.1016/S0140-6736(05)66544-0CrossRef Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005,365(9472):1687-717. 10.1016/S0140-6736(05)66544-0CrossRef
2.
go back to reference Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007, 84: 102-103. 10.1016/j.radonc.2007.05.011CrossRef Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007, 84: 102-103. 10.1016/j.radonc.2007.05.011CrossRef
3.
go back to reference Overgaard M, Hansen PS, Overgaard J, et al.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337: 949-955. 10.1056/NEJM199710023371401CrossRefPubMed Overgaard M, Hansen PS, Overgaard J, et al.: Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997, 337: 949-955. 10.1056/NEJM199710023371401CrossRefPubMed
4.
go back to reference Overgaard M, Christensen JJ, Johansen H, et al.: Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. Int J Radiat Oncol Biol Phys 1990, 19: 1121-1124. 10.1016/0360-3016(90)90214-5CrossRefPubMed Overgaard M, Christensen JJ, Johansen H, et al.: Evaluation of radiotherapy in high-risk breast cancer patients: report from the Danish Breast Cancer Cooperative Group (DBCG 82) Trial. Int J Radiat Oncol Biol Phys 1990, 19: 1121-1124. 10.1016/0360-3016(90)90214-5CrossRefPubMed
5.
go back to reference Eifel P, Axelson JA, Costa J, et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001, 93: 979-989. 10.1093/jnci/93.13.979CrossRefPubMed Eifel P, Axelson JA, Costa J, et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001, 93: 979-989. 10.1093/jnci/93.13.979CrossRefPubMed
6.
go back to reference Kunkler IH, Canney P, van TG, et al.: Elucidating the role of chest wall irradiation in intermediate risk breast cancer: The MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol) 2008, 20: 31-34.CrossRef Kunkler IH, Canney P, van TG, et al.: Elucidating the role of chest wall irradiation in intermediate risk breast cancer: The MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol) 2008, 20: 31-34.CrossRef
7.
go back to reference Ragaz J, Olivotto IA, Spinelli JJ, et al.: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005, 97: 116-126. 10.1093/jnci/djh297CrossRefPubMed Ragaz J, Olivotto IA, Spinelli JJ, et al.: Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005, 97: 116-126. 10.1093/jnci/djh297CrossRefPubMed
8.
go back to reference Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ: Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999, 44: 989-990. 10.1016/S0360-3016(99)00096-6CrossRefPubMed Harris JR, Halpin-Murphy P, McNeese M, Mendenhall NP, Morrow M, Robert NJ: Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999, 44: 989-990. 10.1016/S0360-3016(99)00096-6CrossRefPubMed
9.
go back to reference Recht A, Edge SB, Solin LJ, et al.: American Society of Clinical Oncology. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19: 1539-1569.PubMed Recht A, Edge SB, Solin LJ, et al.: American Society of Clinical Oncology. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19: 1539-1569.PubMed
10.
go back to reference Recht A, Bartelink H, Fourquet A, et al.: Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol 1998, 16: 886-2889. Recht A, Bartelink H, Fourquet A, et al.: Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol 1998, 16: 886-2889.
11.
go back to reference Truong PT, Berthlet E, Lee J et al: The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005, 103: 2006-2014. 10.1002/cncr.20969CrossRefPubMed Truong PT, Berthlet E, Lee J et al: The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005, 103: 2006-2014. 10.1002/cncr.20969CrossRefPubMed
12.
go back to reference Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G: The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 2004, 70: 225-230. 10.1016/j.radonc.2003.10.015CrossRefPubMed Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G: The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 2004, 70: 225-230. 10.1016/j.radonc.2003.10.015CrossRefPubMed
13.
go back to reference Van der Wal BCH, Butzelaar RMJM, van der Meij S, Boermeester MA: Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in Stage I and II breast cancer. Eur J Surg Oncol 2002, 28: 481-489. 10.1053/ejso.2002.1239CrossRefPubMed Van der Wal BCH, Butzelaar RMJM, van der Meij S, Boermeester MA: Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in Stage I and II breast cancer. Eur J Surg Oncol 2002, 28: 481-489. 10.1053/ejso.2002.1239CrossRefPubMed
14.
go back to reference Megale Costa LJ, Soares HP, Gaspar HA, et al.: Ratio between positive lymph nodes and total dissected axillary lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004, 27: 304-306. 10.1097/01.COC.0000071941.70772.DCCrossRefPubMed Megale Costa LJ, Soares HP, Gaspar HA, et al.: Ratio between positive lymph nodes and total dissected axillary lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004, 27: 304-306. 10.1097/01.COC.0000071941.70772.DCCrossRefPubMed
15.
go back to reference Truong PT, Olivotto IA, Kader HA, et al.: Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2005, 61: 1337-1347. 10.1016/j.ijrobp.2004.08.009CrossRefPubMed Truong PT, Olivotto IA, Kader HA, et al.: Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2005, 61: 1337-1347. 10.1016/j.ijrobp.2004.08.009CrossRefPubMed
16.
go back to reference Russell NS, Kunkler IH, Tienhoven G, Canney PA, Thomas J, Bartlett J, et al.: Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate? J Clin Oncol 2009,27(6):996-997. 10.1200/JCO.2008.18.7062CrossRefPubMed Russell NS, Kunkler IH, Tienhoven G, Canney PA, Thomas J, Bartlett J, et al.: Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate? J Clin Oncol 2009,27(6):996-997. 10.1200/JCO.2008.18.7062CrossRefPubMed
17.
go back to reference Arriagada R, Lê MG: Number of positive axillary lymph nodes and post-mastectomy radiotherapy effectin breast cancer patients. Radiother Oncol 2007,84(1):102-103. 10.1016/j.radonc.2007.05.011CrossRefPubMed Arriagada R, Lê MG: Number of positive axillary lymph nodes and post-mastectomy radiotherapy effectin breast cancer patients. Radiother Oncol 2007,84(1):102-103. 10.1016/j.radonc.2007.05.011CrossRefPubMed
18.
go back to reference Cheng SH, Horng CF, West M, et al.: Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006, 24: 4594-602. 10.1200/JCO.2005.02.5676CrossRefPubMed Cheng SH, Horng CF, West M, et al.: Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006, 24: 4594-602. 10.1200/JCO.2005.02.5676CrossRefPubMed
19.
go back to reference Val Gebski, Marivic Lagleva, Anthony Keech, John Simes, Langlands AllanO: Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective. J Natl Cancer Inst 2006,98(1):26-38. 10.1093/jnci/djj002CrossRef Val Gebski, Marivic Lagleva, Anthony Keech, John Simes, Langlands AllanO: Survival Effects of Postmastectomy Adjuvant Radiation Therapy Using Biologically Equivalent Doses: A Clinical Perspective. J Natl Cancer Inst 2006,98(1):26-38. 10.1093/jnci/djj002CrossRef
20.
go back to reference Giardona SH, Kuo YF, Freeman JL, et al.: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005, 97: 419-424. 10.1093/jnci/dji067CrossRef Giardona SH, Kuo YF, Freeman JL, et al.: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005, 97: 419-424. 10.1093/jnci/dji067CrossRef
21.
go back to reference Rutqvist LE, Rose C, Cavallin-Stahl E: A systematic overview of radiation therapy effects in breast cancer. Acta Oncol 2003, 42: 532-545. 10.1080/02841860310014444CrossRefPubMed Rutqvist LE, Rose C, Cavallin-Stahl E: A systematic overview of radiation therapy effects in breast cancer. Acta Oncol 2003, 42: 532-545. 10.1080/02841860310014444CrossRefPubMed
22.
go back to reference Van de Steene J, Soete G, Storme G: Adjuvant radiotherapy for breast cancer significantly improves overall survival: The missing link. Radiother Oncol 2000, 55: 263-272. 10.1016/S0167-8140(00)00204-8CrossRefPubMed Van de Steene J, Soete G, Storme G: Adjuvant radiotherapy for breast cancer significantly improves overall survival: The missing link. Radiother Oncol 2000, 55: 263-272. 10.1016/S0167-8140(00)00204-8CrossRefPubMed
23.
go back to reference Whelan TJ, Julian J, Wright J, et al.: Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000, 18: 1220-1229.PubMed Whelan TJ, Julian J, Wright J, et al.: Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000, 18: 1220-1229.PubMed
24.
go back to reference Sotiriou C, Wirapati P, Loi S, et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98: 262-272. 10.1093/jnci/djj052CrossRefPubMed Sotiriou C, Wirapati P, Loi S, et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98: 262-272. 10.1093/jnci/djj052CrossRefPubMed
25.
go back to reference Kreike B, Halfwerk H, Kristel P, et al.: Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res 2006, 12: 5705-5712. 10.1158/1078-0432.CCR-06-0805CrossRefPubMed Kreike B, Halfwerk H, Kristel P, et al.: Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res 2006, 12: 5705-5712. 10.1158/1078-0432.CCR-06-0805CrossRefPubMed
26.
go back to reference Fisher B, Wolmark N, Redmond C, et al.: Findings from NSABP Protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer 1981, 48: 1863-1872. 10.1002/1097-0142(19811015)48:8<1863::AID-CNCR2820480825>3.0.CO;2-UCrossRefPubMed Fisher B, Wolmark N, Redmond C, et al.: Findings from NSABP Protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer 1981, 48: 1863-1872. 10.1002/1097-0142(19811015)48:8<1863::AID-CNCR2820480825>3.0.CO;2-UCrossRefPubMed
Metadata
Title
Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: Is there a role for radiation therapy?
Authors
Rusen Cosar
Cem Uzal
Fusun Tokatli
Bengu Denizli
Mert Saynak
Nesrin Turan
Sernaz Uzunoglu
Alaattin Ozen
Atakan Sezer
Kamuran Ibis
Burcu Uregen
Vuslat Yurut-Caloglu
Zafer Kocak
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-28

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue